Cargando…
A Steady‐State Head‐to‐Head Pharmacokinetic Comparison of All FK‐506 (Tacrolimus) Formulations (ASTCOFF): An Open‐Label, Prospective, Randomized, Two‐Arm, Three‐Period Crossover Study
This two‐sequence, three‐period crossover study is the first pharmacokinetic (PK) study to compare all three innovator formulations of tacrolimus (twice‐daily immediate‐release tacrolimus capsules [IR‐Tac]; once‐daily extended‐release tacrolimus capsules [ER‐Tac]; novel once‐daily tacrolimus tablets...
Autores principales: | Tremblay, S., Nigro, V., Weinberg, J., Woodle, E. S., Alloway, R. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297985/ https://www.ncbi.nlm.nih.gov/pubmed/27340950 http://dx.doi.org/10.1111/ajt.13935 |
Ejemplares similares
-
Maculopathy Associated with Tacrolimus (FK 506)
por: Koh, Taehyuk, et al.
Publicado: (2011) -
Advancing Nerve Regeneration: Translational Perspectives of Tacrolimus (FK506)
por: Daeschler, Simeon C., et al.
Publicado: (2023) -
Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury
por: Yousuf, Seema, et al.
Publicado: (2011) -
A case of reversible toxic optic neuropathy from tacrolimus (FK506)
por: Gokoffski, Kimberly K., et al.
Publicado: (2020) -
Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines
por: Capone, Francesca, et al.
Publicado: (2014)